Product Images Memantine Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 13 images provide visual information about the product associated with Memantine Hydrochloride NDC 65862-653 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1: Time course of the change from baseline in ADCS-ADL score for patients completing 28 weeks of treatment. - memantine fig 1

Figure 1: Time course of the change from baseline in ADCS-ADL score for patients completing 28 weeks of treatment. - memantine fig 1

Figure 2: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. - memantine fig 2

Figure 2: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. - memantine fig 2

Figure 3: Time course of the change from baseline in SIB score for patients completing 28 weeks of treatment. - memantine fig 3

Figure 3: Time course of the change from baseline in SIB score for patients completing 28 weeks of treatment. - memantine fig 3

Figure 4: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. - memantine fig 4

Figure 4: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. - memantine fig 4

Figure 5: Time course of the change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment. - memantine fig 5

Figure 5: Time course of the change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment. - memantine fig 5

Figure 6: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. - memantine fig 6

Figure 6: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. - memantine fig 6

Figure 7: Time course of the change from baseline in SIB score for patients completing 24 weeks of treatment. - memantine fig 7

Figure 7: Time course of the change from baseline in SIB score for patients completing 24 weeks of treatment. - memantine fig 7

Figure 8: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in SIB scores. - memantine fig 8

Figure 8: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in SIB scores. - memantine fig 8

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg Blister Carton (10 x 10 Unit-dose) - memantine fig10

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg Blister Carton (10 x 10 Unit-dose) - memantine fig10

This appears to be a label for Memantine Hydrochloride Tablets USP, containing information about dosage and storage conditions. The tablets are manufactured by Aurobindo Pharma and come in a package of 100 unit-dose tablets. The label also includes a list of ingredients and precautions for storage.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg (60 Tablets Bottle) - memantine fig11

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg (60 Tablets Bottle) - memantine fig11

This is a prescription drug with the name Memantine Hydrochloride. It is manufactured in India by Aurobindo Pharma USA, Inc. Each film-coated tablet contains 10 mg of memantine hydrochloride USP. The recommended dosage and full prescribing information can be found in the package insert. The tablets should be stored at controlled room temperature and dispensed in a tightly closed container as described in the USP. The NDC code for this product is 65862-653-60.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg Blister Carton (10 x 10 Unit-dose) - memantine fig12

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg Blister Carton (10 x 10 Unit-dose) - memantine fig12

The text appears to be a label of medication called "Memantine Hydrochloride Tablets USP". The medication comes in packages containing 20 tablets with a dosage strength of 10 mg. The label also includes instructions for storage and usage.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg (60 Tablets Bottle) - memantine fig9

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg (60 Tablets Bottle) - memantine fig9

NDG 65862-652go E26h is a medication in tablet form that contains mg of memantine hydrochloride USP. It is distributed by Aurabindo Pharma USA, Inc and manufactured in India. The usual dosage is specified on the packaging for Lot MO and the medication is only available with a prescription. The medication should be stored at room temperature between 20° to 25°C (68° to 77°F). The medication should be kept out of the reach of children. The text includes a printing zone coding area and dotted lines that should not be printed.*

Memantine Structure - memantine str

Memantine Structure - memantine str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.